Bringing model systems closer to the clinic
Goal of the clonal redesign lab is to change a tumor’s environment so as to favor certain tumor subclones over others. We will redesign a tumor’s fitness landscape, rather than directly the clones themselves. Why then clonal redesign? Because by redesigning the environment, adaptation of clones to the new environment is implicit. Anticipating and preparing for this adaptation is at the core of our lab.
WELCOME TO OUR PERSONALIZED ONCOLOGY PLATFORM
We combine computational biology, mathematical modeling and pharmacology to up our odds in the race against tumor evolution.
Our research program runs on two parallel tracks, the first complementing and supporting the second. The first track aims to improve consilience among clone perspectives: developing methods to quantify the clonal composition of a tumor from different perspectives, such as their genome, transcriptome, or appearance, and integrating those methods with each other. In short, the first track characterizes clones. The second track uses these clone characteristics to make treatment predictions.
Andor/Gomes Joint Christmas Party
IMO X Winners!
CRD lab was awarded the NCI's R37, dedicated to quantify the cost to benefit ratio of high ploidy and explain inter-tumoral differences in DNA content. Collaboration with many brilliant minds at Moffitt, including Ana Gomes, Sandy Anderson, Xiaoqing Yu, and Andriy Marusyk. At least 5 and up to 7 years of non-competitive funding! Let the journey begin! 8/22/2022
CRD lab was selected to receive the 2022 Evolutionary Therapy award to evaluate aneuploidy as biomarker of cell fate. Exciting collaboration with Dr. Ana Gomes! 3/21/2022
Our R03 grant was awarded to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments.
Wonderful international collaborations with Laura Heiser (OHSU), Zaid Siddiqui (UPMC) and Saeed Alahmari.
Our Perspective on the building blocks of DNA as candidate rate-limiting factors for the evolution of high-ploidy cancer cells is out in Cancer Research.
Richard Beck joins the CRD lab as postdoctoral fellow in computational biology. Richard brings strong skills in quantitative biology as well as math. modeling, which he will combine to develop data driven mathematical models. Welcome Richard!
Pallavi Singh and Navami Jain started their summer internships, working on feature selection to integrate imaging and single-cell sequencing data. Welcome Pallavi & Navami!
Welcome Andrew Schultz to our lab! Andrew will run our cell culture lab while also crunching numbers to find expression signatures of O2 and PO4 availability in the microenvironment.
What cost do cells with a higher DNA content pay for the robustness benefit it provides? Mathonco, RNASeq and microenvironment profiling join forces to find out! Thrilled to share our first paper from the clonal redesign lab.
Opinion on what it takes to practice for the worst-case scenario of cancer biology and why it’s necessary on the Mathoncoblog.
Our paper on in-vitro adaptation, evolution and heterogeneity of cancer cell lines is published.
Tremendously excited to welcome Thomas Veith as the 1st PhD student in the clonal redesign lab! Thomas is a PhD candidate studying Integrated Mathematical Oncology. He will embark on understanding how in-vitro cellular heterogeneity emerges and is maintained.
Welcome to Bradley Fox into the lab! Bradley is part of the off-campus program IMO is organizing for Dartmouth College students. Bradley's work explores the hypothesis that different timings of splitting and passaging a cell line will benefit different co-existing clones.
The Pathway to Independence Award (K99/R00) is funding us